Bristol-myers Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL-MYERS, and when can generic versions of BRISTOL-MYERS drugs launch?
BRISTOL-MYERS has six approved drugs.
There are twenty-one US patents protecting BRISTOL-MYERS drugs.
There are three hundred and eighty-eight patent family members on BRISTOL-MYERS drugs in forty-five countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Bristol-myers
| International Patents: | 388 |
| US Patents: | 21 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Patent Litigation for Bristol-myers: | See patent lawsuits for Bristol-myers |
| PTAB Cases with Bristol-myers as patent owner: | See PTAB cases with Bristol-myers as patent owner |
Drugs and US Patents for Bristol-myers
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 9,101,543*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | 8,900,566 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol-myers | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 9,511,046*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 7,820,788*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol-myers
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | 6,506,405 | ⤷ Try a Trial |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | 6,908,432 | ⤷ Try a Trial |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 6,045,501 | ⤷ Try a Trial |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 8,315,886 | ⤷ Try a Trial |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 8,589,188 | ⤷ Try a Trial |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | 8,589,188 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL-MYERS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
| ➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
| ➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
| ➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
| ➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
International Patents for Bristol-myers Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | I432426 | ⤷ Try a Trial |
| Denmark | 2049522 | ⤷ Try a Trial |
| New Zealand | 576856 | ⤷ Try a Trial |
| Taiwan | I646959 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2012060847 | ⤷ Try a Trial |
| European Patent Office | 1853250 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol-myers Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1951684 | 21C1019 | France | ⤷ Try a Trial | PRODUCT NAME: FEDRATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, OU UN HYDRATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE DICHLORHYDRATE DE FEDRATINIB MONOHYDRATE; REGISTRATION NO/DATE: EU/1/20/1514 20210209 |
| 2049522 | CR 2015 00003 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR OG FARMACEUTISK ACCEPTABLE SALTE DERAF, SAERLIGT DACLATASVIR-DIHYDROCHLORID; REG. NO/DATE: EU/1/14/939 20140826 |
| 2049522 | 211 50001-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: DAKLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939 - EU/1/14/939/004 20140826 |
| 1951684 | 2190016-2 | Sweden | ⤷ Try a Trial | PRODUCT NAME: FEDRATINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE HYDRATE THEREOF, IN PARTICULAR FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE; REG. NO/DATE: EU/1/20/1514 20210209 |
| 2049522 | PA2015006,C2049522 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DAKLATASVIRAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC DAKLATASVIRO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/14/939/001 - EU/1/14/939/004, 2 00140822 |
| 1853250 | CA 2014 00034 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: EU/1/07/428 C(2013)9835 20131230 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
